David A. Siegel Uro Gen Pharma Ltd. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Uro Gen Pharma Ltd. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 24,500 shares of URGN stock, worth $291,795. This represents 0.0% of its overall portfolio holdings.
Number of Shares
24,500
Previous 24,900
1.61%
Holding current value
$291,795
Previous $417,000
25.42%
% of portfolio
0.0%
Previous 0.0%
Shares
10 transactions
Others Institutions Holding URGN
# of Institutions
130Shares Held
35.9MCall Options Held
22KPut Options Held
93.8K-
Rtw Investments, LP New York, NY3.79MShares$45.1 Million0.77% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.74MShares$44.5 Million0.09% of portfolio
-
Menora Mivtachim Holdings Ltd.2.3MShares$27.4 Million0.19% of portfolio
-
Black Rock Inc. New York, NY2.19MShares$26.1 Million0.0% of portfolio
-
Morgan Stanley New York, NY2.18MShares$26 Million0.0% of portfolio
About UroGen Pharma Ltd.
- Ticker URGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 22,740,500
- Market Cap $271M
- Description
- UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization novel solutions for specialty cancers and urothelial diseases. It offers RTGel, a polymeric biocompatible and reverse thermal gelation hydrogel to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead...